Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
36285 | 83 | 32.0 | 77% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
0 | 4 | BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY | 4064930 |
307 | 3 | INTEGRIN//ALPORT SYNDROME//LAMININ | 40384 |
683 | 2 | INTEGRIN//FOCAL ADHESION KINASE//TENASCIN C | 13145 |
36285 | 1 | RECOMBINANT FIBRONECTIN FRAGMENT//CBD HEPII POLYPEPTIDE//ND2001 | 83 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | RECOMBINANT FIBRONECTIN FRAGMENT | authKW | 1839498 | 6% | 100% | 5 |
2 | CBD HEPII POLYPEPTIDE | authKW | 735799 | 2% | 100% | 2 |
3 | ND2001 | authKW | 662217 | 4% | 60% | 3 |
4 | ARG GLY ASP SER RGDS | authKW | 551846 | 4% | 50% | 3 |
5 | ASAKA S | address | 490531 | 2% | 67% | 2 |
6 | ADENOID CYSTIC CARCINOMA ACE | authKW | 367900 | 1% | 100% | 1 |
7 | ARG GLY ASP SER ANALOG | authKW | 367900 | 1% | 100% | 1 |
8 | ARG GLY ASP SER RGDS ANALOGUE | authKW | 367900 | 1% | 100% | 1 |
9 | ARG LEU ASP SER RLDS ANALOGUE | authKW | 367900 | 1% | 100% | 1 |
10 | CBD AND HEPII DOMAINS | authKW | 367900 | 1% | 100% | 1 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Oncology | 797 | 51% | 0% | 42 |
2 | Medicine, Research & Experimental | 73 | 12% | 0% | 10 |
3 | Pharmacology & Pharmacy | 63 | 18% | 0% | 15 |
4 | Biochemistry & Molecular Biology | 24 | 18% | 0% | 15 |
5 | Biophysics | 16 | 6% | 0% | 5 |
6 | Polymer Science | 8 | 5% | 0% | 4 |
7 | Chemistry, Applied | 8 | 4% | 0% | 3 |
8 | Biotechnology & Applied Microbiology | 5 | 5% | 0% | 4 |
9 | Materials Science, Biomaterials | 3 | 1% | 0% | 1 |
10 | Gastroenterology & Hepatology | 2 | 2% | 0% | 2 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | ASAKA S | 490531 | 2% | 67% | 2 |
2 | IMMUNOL SCI KITA15 NISHI7 KITA KU | 367900 | 1% | 100% | 1 |
3 | INTER EGIATE BIOTECHNOL MED | 367900 | 1% | 100% | 1 |
4 | MOL CELLULAR PATHOL PATHOPHYSIOL | 367900 | 1% | 100% | 1 |
5 | PATHOGEN BIOCHEM WAKAN YAKU | 367900 | 1% | 100% | 1 |
6 | WAKAN YAKU TRAD SINO J ANESE MED | 367900 | 1% | 100% | 1 |
7 | CHEM CHEM ENGNENGN BIONANOTECHNOL | 183949 | 1% | 50% | 1 |
8 | IMMUNOL SCI KITA 15 NISHI 7 KITA KU | 183949 | 1% | 50% | 1 |
9 | RADIOBIOCHEM PHARMACEUT SCI | 183949 | 1% | 50% | 1 |
10 | SCI POLYMER SCI KITA KU | 163508 | 2% | 22% | 2 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | JAPANESE JOURNAL OF CANCER RESEARCH | 12578 | 13% | 0% | 11 |
2 | CLINICAL & EXPERIMENTAL METASTASIS | 4607 | 6% | 0% | 5 |
3 | ANTI-CANCER DRUGS | 2816 | 6% | 0% | 5 |
4 | CLINICAL IMMUNOTHERAPEUTICS | 1464 | 1% | 0% | 1 |
5 | ONCOLOGY RESEARCH | 1224 | 2% | 0% | 2 |
6 | PREPARATIVE BIOCHEMISTRY & BIOTECHNOLOGY | 448 | 1% | 0% | 1 |
7 | JOURNAL OF BIOACTIVE AND COMPATIBLE POLYMERS | 413 | 1% | 0% | 1 |
8 | CELLULAR & MOLECULAR BIOLOGY LETTERS | 364 | 1% | 0% | 1 |
9 | TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE | 315 | 2% | 0% | 2 |
10 | JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY | 303 | 2% | 0% | 2 |
Author Key Words |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | RECOMBINANT FIBRONECTIN FRAGMENT | 1839498 | 6% | 100% | 5 | Search RECOMBINANT+FIBRONECTIN+FRAGMENT | Search RECOMBINANT+FIBRONECTIN+FRAGMENT |
2 | CBD HEPII POLYPEPTIDE | 735799 | 2% | 100% | 2 | Search CBD+HEPII+POLYPEPTIDE | Search CBD+HEPII+POLYPEPTIDE |
3 | ND2001 | 662217 | 4% | 60% | 3 | Search ND2001 | Search ND2001 |
4 | ARG GLY ASP SER RGDS | 551846 | 4% | 50% | 3 | Search ARG+GLY+ASP+SER+RGDS | Search ARG+GLY+ASP+SER+RGDS |
5 | ADENOID CYSTIC CARCINOMA ACE | 367900 | 1% | 100% | 1 | Search ADENOID+CYSTIC+CARCINOMA+ACE | Search ADENOID+CYSTIC+CARCINOMA+ACE |
6 | ARG GLY ASP SER ANALOG | 367900 | 1% | 100% | 1 | Search ARG+GLY+ASP+SER+ANALOG | Search ARG+GLY+ASP+SER+ANALOG |
7 | ARG GLY ASP SER RGDS ANALOGUE | 367900 | 1% | 100% | 1 | Search ARG+GLY+ASP+SER+RGDS+ANALOGUE | Search ARG+GLY+ASP+SER+RGDS+ANALOGUE |
8 | ARG LEU ASP SER RLDS ANALOGUE | 367900 | 1% | 100% | 1 | Search ARG+LEU+ASP+SER+RLDS+ANALOGUE | Search ARG+LEU+ASP+SER+RLDS+ANALOGUE |
9 | CBD AND HEPII DOMAINS | 367900 | 1% | 100% | 1 | Search CBD+AND+HEPII+DOMAINS | Search CBD+AND+HEPII+DOMAINS |
10 | EILDV | 367900 | 1% | 100% | 1 | Search EILDV | Search EILDV |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | WEI, J , XIONG, YQ , (2007) INHIBITORY EFFECT OF RECOMBINANT FIBRONECTIN POLYPEPTIDE CH50 ON INVASION AND METASTASIS OF MELANOMA B16 CELLS.JOURNAL OF HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY-MEDICAL SCIENCES. VOL. 27. ISSUE 1. P. 17-19 | 5 | 83% | 0 |
2 | SAIKI, I , (1997) CELL ADHESION MOLECULES AND CANCER METASTASIS.JAPANESE JOURNAL OF PHARMACOLOGY. VOL. 75. ISSUE 3. P. 215-242 | 25 | 21% | 59 |
3 | FUJII, H , NISHIKAWA, N , KOMAZAWA, H , SUZUKI, M , KOJIMA, M , ITOH, I , OBATA, A , AYUKAWA, K , AZUMA, I , SAIKI, I , (1998) A NEW PSEUDO-PEPTIDE OF ARG-GLY-ASP (RGD) WITH INHIBITORY EFFECT ON TUMOR METASTASIS AND ENZYMATIC DEGRADATION OF EXTRACELLULAR MATRIX.CLINICAL & EXPERIMENTAL METASTASIS. VOL. 16. ISSUE 1. P. 94 -104 | 12 | 43% | 13 |
4 | OHNISHI, Y , FUJII, H , MURAKAMI, K , SAKAMOTO, T , TSUKADA, K , FUJIMAKI, M , KOJIMA, M , SAIKI, I , (1998) A NEW PSEUDO-PEPTIDE ANALOGUE OF THE ARG-GLY-ASP (RGD) SEQUENCE INHIBITS LIVER METASTASIS OF COLON 26-L5 CARCINOMA CELLS.CANCER LETTERS. VOL. 124. ISSUE 2. P. 157 -163 | 10 | 50% | 10 |
5 | SAIKI, I , (1994) ANTIADHESION PEPTIDES IN THE PREVENTION OF TUMOR-METASTASIS.CLINICAL IMMUNOTHERAPEUTICS. VOL. 1. ISSUE 4. P. 307-318 | 15 | 34% | 1 |
6 | FUJII, H , NISHIKAWA, N , KOMAZAWA, H , ORIKASA, A , ONO, M , ITOH, I , MURATA, J , AZUMA, I , SAIKI, I , (1996) INHIBITION OF TUMOR INVASION AND METASTASIS BY PEPTIDIC MIMETICS OF ARG-GLY ASP (RGD) DERIVED FROM THE CELL RECOGNITION SITE OF FIBRONECTIN.ONCOLOGY RESEARCH. VOL. 8. ISSUE 9. P. 333-342 | 11 | 41% | 15 |
7 | OKU, N , KOIKE, C , TOKUDOME, Y , OKADA, S , NISHIKAWA, N , TSUKADA, H , KISO, M , HASEGAWA, A , FUJII, H , MURATA, J , ET AL (1997) APPLICATION OF LIPOSOMES FOR CANCER METASTASIS.ADVANCED DRUG DELIVERY REVIEWS. VOL. 24. ISSUE 2-3. P. 215 -223 | 9 | 43% | 15 |
8 | TSUCHIYA, Y , SAWADA, S , TSUKADA, K , SAIK, I , (2002) A NEW PSEUDO-PEPTIDE OF ARG-GLY-ASP (RGD) INHIBITS INTRAHEPATIC METASTASIS OF ORTHOTOPICALLY IMPLANTED MURINE HEPATOCELLULAR CARCINOMA.INTERNATIONAL JOURNAL OF ONCOLOGY. VOL. 20. ISSUE 2. P. 319 -324 | 8 | 31% | 20 |
9 | WANG, SM , ZHU, J , LIU, YK , (2016) A NOVEL ANTI-ADHESION PEPTIDE (BETA 3) INHIBITS HEPATOCELLULAR CARCINOMA ACTIVITY IN VITRO AND IN VIVO.ONCOLOGY LETTERS. VOL. 12. ISSUE 6. P. 4744 -4748 | 5 | 33% | 0 |
10 | KOMAZAWA, H , FUJII, H , KOJIMA, M , MORI, H , ONO, M , ITOH, I , AZUMA, I , SAIKI, I , (1995) COMBINATION OF ANTI-CELL ADHESIVE SYNTHETIC ARG-GLY-ASP-SER ANALOG AND ANTICANCER DRUG DOXORUBICIN HEIGHTENS THEIR ORIGINAL ANTIMETASTATIC ACTIVITIES.ONCOLOGY RESEARCH. VOL. 7. ISSUE 7-8. P. 341-351 | 10 | 30% | 4 |
Classes with closest relation at Level 1 |